Novo Nordisk backer buys Catalent for $16.5 billion

It would appear pharmaceuticals and biotechnology is still a fertile industry for dealmaking.

Novo Holdings, the largest shareholder in Danish drugs giant Novo Nordisk, just announced the $16.5 billion takeover of US-listed Catalent, provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products...